Form 4 for IMNM Immunome Inc.
Accepted 2025-12-22 00:00:00 ET · period of report 2025-12-19 · accession 0001167496-25-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-22 | 2025-12-19 | IMNM | SIEGALL CLAY B | Pres, CEO, Dir | G - Gift | $0.00 | -200.0K | 660.5K | -23% | $0 | |
| 2025-12-22 | 2025-12-19 | IMNM | SIEGALL CLAY B | Pres, CEO, Dir | P - Purchase | $20.48 | +7,278 | 860.5K | +0.9% | +$149.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-19 | G | D | 200,000 | $0.00 | 660,525 | D | — | — | (F3) The shares are subject to a lockup agreement entered into by the Reporting Person on December 15, 2025 (the "Lock-Up Agreement"). The transferee has agreed to be bound by the terms of the Lock-Up Agreement. |
| 2 | Common | Common Stock | 2025-12-19 | P | A | 7,278 | $20.48 | 860,525 | D | — | — | (F1) The weighted average purchase price for the transaction report was $20.48, and the range of prices were between $20.36 and $20.50, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. |